» Articles » PMID: 38377680

Behavioral and Neurophysiological Implications of Pathological Human Tau Expression in Serotonin Neurons

Overview
Specialty Neurology
Date 2024 Feb 20
PMID 38377680
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a progressive degenerative disorder that results in a severe loss of brain cells and irreversible cognitive decline. Memory problems are the most recognized symptoms of AD. However, approximately 90% of patients diagnosed with AD suffer from behavioral symptoms, including mood changes and social impairment years before cognitive dysfunction. Recent evidence indicates that the dorsal raphe nucleus (DRN) is among the initial regions that show tau pathology, which is a hallmark feature of AD. The DRN harbors serotonin (5-HT) neurons, which are critically involved in mood, social, and cognitive regulation. Serotonergic impairment early in the disease process may contribute to behavioral symptoms in AD. However, the mechanisms underlying vulnerability and contribution of the 5-HT system to AD progression remain unknown. Here, we performed behavioral and electrophysiological characterizations in mice expressing a phosphorylation-prone form of human tau (hTauP301L) in 5-HT neurons. We found that pathological tau expression in 5-HT neurons induces anxiety-like behavior and alterations in stress-coping strategies in female and male mice. Female mice also exhibited social disinhibition and mild cognitive impairment in response to 5-HT neuron-specific hTauP301L expression. Behavioral alterations were accompanied by disrupted 5-HT neuron physiology in female and male hTauP301L expressing mice with exacerbated excitability disruption in females only. These data provide mechanistic insights into the brain systems and symptoms impaired early in AD progression, which is critical for disease intervention.

Citing Articles

Deciphering the Functions of Raphe-Hippocampal Serotonergic and Glutamatergic Circuits and Their Deficits in Alzheimer's Disease.

Yu W, Zhang R, Zhang A, Mei Y Int J Mol Sci. 2025; 26(3).

PMID: 39941002 PMC: 11818420. DOI: 10.3390/ijms26031234.


SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease.

Terstege D, Jabeen S, Galea L, Epp J, Sargin D Alzheimers Dement. 2025; 21(2):e14579.

PMID: 39935329 PMC: 11814539. DOI: 10.1002/alz.14579.

References
1.
Chen C, Eastwood S, Hope T, McDonald B, Francis P, Esiri M . Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol. 2000; 26(4):347-55. DOI: 10.1046/j.1365-2990.2000.00254.x. View

2.
Lee K, Coelho M, Sern K, Class M, Bocz M, Szumlinski K . Anxiolytic effects of buspirone and MTEP in the Porsolt Forced Swim Test. Chronic Stress (Thousand Oaks). 2017; 1. PMC: 5584874. DOI: 10.1177/2470547017712985. View

3.
Ismail Z, Smith E, Geda Y, Sultzer D, Brodaty H, Smith G . Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2015; 12(2):195-202. PMC: 4684483. DOI: 10.1016/j.jalz.2015.05.017. View

4.
Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

5.
Gualtieri C, Johnson L . Age-related cognitive decline in patients with mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(4):962-7. DOI: 10.1016/j.pnpbp.2007.12.030. View